BTG chief Dame Louise Makin nets £18million payout after acquisition by US pharmaceuticals titan

The chief executive of former stock market darling BTG has pocketed £18m from its sale to a US pharmaceuticals titan.

Dame Louise Makin was handed the payout after overseeing serious illness specialist BTG’s £3.3bn acquisition by Boston Scientific.

Makin, 58, ran BTG for 14 years as a listed company. 

The Boston takeover valued shares at 840p each – 37pc more than their value on the stock market at the time.

Kerching! Dame Louise Makin picked up the money as her bonus schemes paid out when the deal with Boston Scientific was completed, earlier this summer

Kerching! Dame Louise Makin picked up the money as her bonus schemes paid out when the deal with Boston Scientific was completed, earlier this summer

She picked up the money as her bonus schemes paid out when the deal completed.

BTG was set up in 1948 as the state-owned National Research Development Corporation to help private companies make money from publicly funded research.

It was privatised in 1992 and now focuses on interventional medicine for diseases such as liver cancer.

 





READ SOURCE

READ  Why Turkey's Trials Are Rippling Into Europe

WHAT YOUR THOUGHTS

Please enter your comment!
Please enter your name here